Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
Obstet Med ; 10(2): 93-95, 2017 Jun.
Article in English | MEDLINE | ID: mdl-28680471

ABSTRACT

We present a case report of transient fetal anhydramnios following maternal non-steroidal anti-inflammatory drug use in pregnancy. This reduction in liquor volume resolved following cessation of the medication with no obvious ill-effect on neonatal outcome. The case report is followed by a comprehensive summary of the relevant literature.

2.
Acta Psychol (Amst) ; 106(1-2): 51-68, 2001 Jan.
Article in English | MEDLINE | ID: mdl-11256339

ABSTRACT

Andries Sanders' dissertation examined selective mechanisms in the functional visual field, and much of his work since has been concerned with the stages that underlie visual information processing particularly while making saccades. We argue that the study of orienting in the functional visual field is timely because it deals with the relation of covert attention shifts, eye movements and head movements to their underlying neurology. In our paper we develop a method to study learning of sequences at all ages from infants to adults. Our studies focus on how learning influences anticipatory eye movements. We examined the learning of unambiguous and context dependent sequences by 4-, 10-, and 18-month-old infants and undergraduates. We found clear learning of unambiguous sequences at 4 months, but learning of context dependent associations was found only in 18-month-olds and in adults. We hypothesize that the learning of unambiguous sequences by 4-month-olds reflects maturation of a basal ganglia-parietal circuit related to adult implicit learning, while the learning of context dependent sequences requires development of frontal structures underlying more general attentional abilities.


Subject(s)
Child Development/physiology , Saccades/physiology , Visual Fields/physiology , Adult , Brain/physiology , Humans , Infant
3.
Am J Clin Nutr ; 72(1): 49-55, 2000 Jul.
Article in English | MEDLINE | ID: mdl-10871560

ABSTRACT

BACKGROUND: In 1997, the US Food and Drug Administration passed a unique ruling that allowed oat bran to be registered as the first cholesterol-reducing food at a dosage of 3 g beta-glucan/d. OBJECTIVE: The effects of a low dose of oat bran in the background diet only were investigated in volunteers with mild-to-moderate hyperlipidemia. DESIGN: The study was a double-blind, placebo-controlled, randomized, parallel study. Sixty-two healthy men (n = 31) and women (n = 31) were randomly allocated to consume either 20 g oat bran concentrate (OBC; containing 3 g beta-glucan) or 20 g wheat bran (control) daily for 8 wk. Fasting blood samples were collected at weeks -1, 0, 4, 8, and 12. A subgroup (n = 17) was studied postprandially after consumption of 2 meals (containing no OBC or wheat bran) at baseline and after supplementation. Fasting plasma samples were analyzed for total cholesterol, HDL cholesterol, triacylglycerol, glucose, and insulin. LDL cholesterol was measured by using the Friedewald formula. The postprandial samples were anlayzed for triacylglycerol, glucose, and insulin. RESULTS: No significant difference was observed in fasting plasma cholesterol, LDL cholesterol, glucose, or insulin between the OBC and wheat-bran groups. HDL-cholesterol concentrations fell significantly from weeks 0 to 8 in the OBC group (P = 0.05). There was a significant increase in fasting glucose concentrations after both OBC (P = 0.03) and wheat-bran (P = 0.02) consumption. No significant difference was found between the OBC and wheat-bran groups in any of the postprandial variables measured. CONCLUSIONS: A low dosage of beta-glucan (3 g/d) did not significantly reduce total cholesterol or LDL cholesterol in volunteers with plasma cholesterol concentrations representative of a middle-aged UK population.


Subject(s)
Diet , Glucans/administration & dosage , Hyperlipidemias/blood , Lipoproteins/blood , Adult , Aged , Blood Glucose/metabolism , Cholesterol, HDL/blood , Cholesterol, LDL/blood , Double-Blind Method , Female , Humans , Hyperlipidemias/diet therapy , Insulin/blood , Male , Middle Aged , Triglycerides/blood
4.
Br J Nutr ; 82(1): 23-30, 1999 Jul.
Article in English | MEDLINE | ID: mdl-10655953

ABSTRACT

The present study was carried out to examine the effect of the daily intake of 10 g inulin on fasting blood lipid, glucose and insulin levels in healthy middle-aged men and women with moderately raised total plasma cholesterol (TC) and triacylglycerol (TAG) levels. This study was a double-blind randomized placebo-controlled parallel study in which fifty-four middle-aged subjects received either inulin or placebo for a period of 8 weeks. Fasting blood samples were collected before the supplementation period (baseline samples 1 and 2, separated by 1 week) and at weeks 4 and 8, with a follow-up at week 12. Compared with baseline values, insulin concentrations were significantly lower at 4 weeks (P < 0.01) in the inulin group. There was a trend for TAG values, compared with baseline, to be lower in the inulin group at 8 weeks (P < 0.08) returning to baseline concentrations at week 12. On comparison of the inulin and placebo groups, the fasting TAG responses over the 8-week test period were shown to be significantly different (P < 0.05, repeated measures ANOVA), which was largely due to lower plasma TAG levels in the inulin group at week 8. The percentage change in TAG levels in the inulin group during the 8-week study was shown to correlate with the initial TAG level of the subjects (rs -0.499, P = 0.004). We therefore conclude that the daily addition of 10 g inulin to the diet significantly reduced fasting insulin concentrations during the 8-week test period and resulted in lower plasma TAG levels, particularly in subjects in whom fasting TAG levels were greater than 1.5 mmol/l. These data support findings from animal studies that fructans influence the formation and/or degradation of TAG-rich lipoprotein particles, and the insulin data are also consistent with recent studies showing attenuation of insulin levels in fructan-treated rats.


Subject(s)
Blood Glucose/drug effects , Insulin/blood , Inulin/pharmacology , Lipids/blood , Adult , Aged , Analysis of Variance , Blood Glucose/metabolism , Cholesterol/blood , Double-Blind Method , Female , Humans , Male , Middle Aged , Triglycerides/blood
5.
J Biol Chem ; 272(32): 19666-71, 1997 Aug 08.
Article in English | MEDLINE | ID: mdl-9242621

ABSTRACT

Sustained activation of extracellular signal-regulated kinase 1/2 (ERK1/2) is critical for initiating differentiation of the PC12 cell to a sympathetic-like neurone. The neuropeptide, pituitary adenylyl cyclase-activating peptide (PACAP), has been demonstrated to cause cells to adopt a neuronal phenotype, although the mechanism of this activity is unclear. PACAP through its type I receptor stimulates a biphasic activation of ERK1/2; a >10-fold increase within 5 min, followed by a >5-fold increase that is sustained for >/=60 min. An equivalent stimulation is seen in PC12 cells expressing a dominant negative Ras mutant. However, the mitogen-activated kinase/ERK kinase 1/2 (MEK1/2) inhibitor PD98059 blocked both PACAP-induced stimulation of ERK1/2 activity and neurite outgrowth. Thus, the activation signal from the PACAP type I receptor on the ERK1/2 cascade pathway is received downstream of Ras, either at Raf or MEK. Down-regulation of protein kinase C or its inhibition by calphostin C blocked the ability of PACAP to stimulate ERK1/2. We conclude that activation of PACAP type I receptor activates protein kinase C, which then activates the ERK1/2 cascade in a Ras-independent manner at either Raf or MEK1/2.


Subject(s)
Mitogen-Activated Protein Kinase Kinases , Mitogen-Activated Protein Kinases , Neuropeptides/metabolism , Neurotransmitter Agents/metabolism , Pituitary Gland/enzymology , Animals , Calcium-Calmodulin-Dependent Protein Kinases/antagonists & inhibitors , Calcium-Calmodulin-Dependent Protein Kinases/metabolism , Enzyme Activation , Enzyme Inhibitors/pharmacology , Flavonoids/pharmacology , Kinetics , MAP Kinase Kinase 1 , MAP Kinase Kinase 2 , Mitogen-Activated Protein Kinase 1 , Mitogen-Activated Protein Kinase 3 , PC12 Cells , Pituitary Adenylate Cyclase-Activating Polypeptide , Protein Serine-Threonine Kinases/metabolism , Protein-Tyrosine Kinases/metabolism , Rats , Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide , Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide , Receptors, Pituitary Hormone/metabolism , Second Messenger Systems
6.
J Lipid Res ; 38(12): 2558-68, 1997 Dec.
Article in English | MEDLINE | ID: mdl-9458279

ABSTRACT

In order to understand the mechanisms by which fatty acids are taken up by the placenta, the uptake of oleic, linoleic, arachidonic, and docosahexaenoic acids by cultured human placental choriocarcinoma (BeWo) cells was examined. Fatty acid uptake by BeWo cells was temperature-dependent and exhibited saturable kinetics. Oleic acid was taken up least and docosahexaenoic acid most by these cells. Moreover, competitive studies of fatty acid uptake by BeWo cells also indicated preferential uptake compared with oleic acid in the order of docosahexaenoic acid, arachidonic acid, and linoleic acid. Western blot analysis demonstrated that BeWo cells express a protein immunoreactive with antibodies to the human placental plasma membrane fatty acid-binding protein (p-FABPpm). Furthermore, pre-treatment of BeWo cells with these antibodies inhibited most of the uptake of docosahexaenoic (64%) and arachidonic acids (68%) whereas oleic acid uptake was inhibited only 32% compared with the controls treated with preimmune serum. These results clearly demonstrate that the pFABPpm may be involved in the preferential uptake of essential fatty acids (EFA) and their long chain polyunsaturated fatty acids (LCPUFA) by these cells. Studies on the distribution of radiolabeled fatty acids in the cellular lipids of BeWo cells showed that docosahexaenoic acid was incorporated mainly in the triacylglycerol fraction, followed by the phospholipid fraction, whereas for arachidonic acid the reverse was true. The preferential incorporation of docosahexaenoic acid into triacylglycerol suggests that triacylglycerol may play an important role in the placental transport of docosahexaenoic acid to the fetal circulation. Together these results demonstrate the preferential uptake of EFA/LCPUFA by BeWo cells that is most probably mediated via the pFABPpm. We thus propose that the p-FABPpm may be involved in the sequestration of maternal plasma LCPUFA by the placenta.


Subject(s)
Carrier Proteins/metabolism , Choriocarcinoma/metabolism , Fatty Acids/pharmacokinetics , Myelin P2 Protein/metabolism , Neoplasm Proteins , Tumor Suppressor Proteins , Antibodies/immunology , Antibodies/pharmacology , Biological Transport/physiology , Blotting, Western , Carrier Proteins/immunology , Carrier Proteins/isolation & purification , Cell Membrane/metabolism , Fatty Acid-Binding Protein 7 , Fatty Acid-Binding Proteins , Fatty Acids, Essential/pharmacokinetics , Humans , Kinetics , Membrane Proteins/metabolism , Myelin P2 Protein/immunology , Myelin P2 Protein/isolation & purification , Phospholipids/analysis , Temperature , Triglycerides/analysis , Tumor Cells, Cultured
7.
J Cogn Neurosci ; 3(4): 345-50, 1991.
Article in English | MEDLINE | ID: mdl-23967814

ABSTRACT

The posterior visual spatial attention system involves a number of separable computations that allow orienting to visual locations. We have studied one of these computations, inhibition of return, in 3-, 4-, 6-, 12-, and 18--month-old infants and adults. Our results indicate that this computation develops rapidly between 3 and 6 months, in conjunction with the ability to program eye movements to specific locations. These findings demonstrate that an attention computation involving the mid-brain eye movement system develops after the third month of life. We suggest how this development might influence the infant's ability to represent and expect visual objects.

SELECTION OF CITATIONS
SEARCH DETAIL
...